



Cite this: *Nanoscale*, 2020, **12**, 9178

Carbon dots-inspired fluorescent cyclodextrins: competitive supramolecular “off–on” (bio)sensors†

Eduardo De los Reyes-Berbel, ^{a,b} Inmaculada Ortiz-Gomez, ^{b,c}
Mariano Ortega-Muñoz, ^{a,b} Alfonso Salinas-Castillo, ^{b,c}
Luis Fermin Capitan-Valvey, ^{b,c} Fernando Hernandez-Mateo, ^{a,b}
Francisco Javier Lopez-Jaramillo ^{*a,b} and Francisco Santoyo-Gonzalez ^{*a,b}

Chromophore-appended cyclodextrins combine the supramolecular loading capabilities of cyclodextrins (CDs) with the optical properties of the affixed chromophores. Among fluorescent materials, carbon dots (CNDs) are attractive and the feasibility of CND-appended CDs as sensors has been demonstrated by different authors. However, CNDs are intrinsically heterogeneous materials and their ulterior functionalization yields hybrid composites that are not well defined in terms of structure and composition. Inspired by the fluorescence properties of 5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyridine-7-carboxylic acid (IPCA), the most paradigmatic of the molecular fluorophores detected in CNDs, herein we report two highly efficient synthetic chemical strategies for the preparation of IPCA-appended CDs that behave as CND-based CD “turn off–on” biosensors suitable for the analysis of cholesterol and β -galactosidase activity. We have deconstructed the CND–CD systems to demonstrate that (i) the role of CNDs is limited to acting as a support for the molecular fluorophores produced during their synthesis and (ii) the molecular fluorophores suffice for the determination of the enzymatic activity based on the quenching by *p*-nitrophenol as a sacrificial quencher.

Received 5th February 2020

Accepted 7th April 2020

DOI: 10.1039/d0nr01004a

rsc.li/nanoscale

1. Introduction

Chromophore-appended cyclodextrins (CDs) are spectroscopically active colourful systems engineered to exploit synergistically the supramolecular hosting capabilities of these glucose-based macrocycles with the optical properties of the affixed chromophores.^{1,2} These dual conjugates are valuable photochemical molecular devices of paramount importance that have found increasing applications in many different areas with a heavy emphasis on imaging, drug delivery, and sensing. Among chromophores, fluorophores provide high sensitivity in analytical applications and a low detection limit in optical imaging methods. Therefore, fluorophore-appended CDs (FCDs) have

been profusely investigated as fluorescent chemo- and biosensors for detecting a variety of organic and biological compounds.^{3–6} The principle behind FCDs is the effect of the microenvironment surrounding the chromophore on their fluorescence properties. Based on their fluorescence behaviour, two types of molecular-based FCD sensors, namely “turn-off” and “turn-on” FCDs, have been described.^{1,6} For the most abundant “turn-off” FCDs, upon complexation of the analyte, a decrease in the fluorescence intensity is observed while for the “turn-on” FCDs an increase in the fluorescence is detected.

Fluorophores of diverse nature have been incorporated into FCD-based sensors. Classically, various types of molecular fluorophores (aryl derivatives, dansyls, nitrobenzofurans, xanthenes, cyanines, porphyrins, and phthalocyanines, among others) have been used for CD covalent tagging.⁶ Molecular-based FCDs are generally constructed using the tools of synthetic chemistry and chemical strategies that ensure isomeric purity and a unitary degree of substitution of native polyhydroxylated CDs since well-characterized systems are required for better performance in most of the sensing applications. Usually, monosubstituted FCDs are synthesized using multi-step synthetic procedures that enable the realization of a sole FCD regioisomer.

^aDepartment of Organic Chemistry, Biotechnology Institute, Faculty of Sciences, Campus Fuentenueva sn, University of Granada, 18071-Granada, Spain.

E-mail: fljara@ugr.es, fsantoyo@ugr.es

^bUnit of Excellence in Chemistry Applied to Biomedicine and the Environment, University of Granada, Spain

^cDepartment of Analytical Chemistry, Faculty of Sciences, Campus Fuentenueva sn, University of Granada, 18071-Granada, Spain

† Electronic supplementary information (ESI) available: Spectroscopic characterization of new compounds, and ESI schemes, figures, and tables. See DOI: 10.1039/d0nr01004a



The outstanding progress made in recent years on nanotechnology has enabled the elaboration of novel CD-modified nanoparticles (NPs). Diverse inorganic NPs (gold, silver, quantum dots and magnetic NPs) and carbonaceous nanomaterials (fullerenes, nanotubes, graphene and carbon dots) provide suitable platforms for the assembly of CDs on their surfaces.^{7,8} CD-modified NPs combine the supramolecular loading capabilities of CDs with the optical, electronic or magnetic properties of NPs. When these systems are used as fluorescent sensors, NPs behave as chromophores governed by the same principles outlined for their molecular counterparts.

Among fluorescent nanomaterials, metal-free carbon nanodots (CNDs) are leading-edge compounds that have attracted rapidly growing interest because of their outstanding features (cost-efficient and easy preparation, water solubility, low toxicity, biocompatibility, and easy functionalization). CNDs are promising candidates for numerous (bio)applications such as bioimaging, theragnosis, drug delivery and fluorescent (bio) sensing.^{9–12} Nonetheless, despite the extensive use of native CNDs as (bio)sensors, the reported cases of hybrid CND–CD composites are scarce and limited to their implementation in (bio)analytical applications. The “turn-off” detection of selected (bio)analytes (fullerenes,¹³ phenolic compounds,¹⁴ and enzymes^{15–17}) and, alternatively, more elaborated “turn off–on” systems for the biosensing of steroid compounds and cholesterol^{18,19} have been described. In the latter case, the competitive hosting between a sacrificial quencher and the desired analyte is used for the successive depletion (“turn-off” state) and restoration (“turn-on” state) of the fluorescence, with beneficial gains in sensitivity.⁴ From the synthetic point of view, CND–CD composites are usually obtained by the post-synthetic surface modification of already synthesized CNDs. Typically, fluorescent CNDs are treated with a coupling reagent to activate the carboxyl groups on the surface of the CNDs and then reacted with amino-CDs.^{11,13,15,17,18} However, this strategy is not exempt from drawbacks.

A central issue in CNDs is the origin of the photoluminescence. Although the topic is still a subject of debate, some consensus has been established.^{20–22} For bottom-up CNDs obtained by the co-pyrolysis of citric acid (CA) and an amine, it is accepted that luminescence primarily results from the molecular state rather than from size differences.²³ When α,β -bifunctional ethyleneamines (α,β -diamines, β -amino alcohols or α,β -aminothiols) are used, the formation of highly luminescent molecular fluorophores containing a five-membered fused 2-pyridone skeleton has been reported. The citrazinic derivative 5-oxo-1,2,3,5-tetrahydroimidazo[1,2-*a*]pyridine-7-carboxylic acid (IPCA) is the most paradigmatic molecular fluorophore detected (ESI Scheme S1†).^{22–30} The plausible mechanism for the formation of IPCA involves, first, the formation of two amide bonds between CA and the amine group of the dopant agent, followed by an intramolecular nucleophilic attack by the β -heteroatom – N, O or S – of the dopant amine to form the five-membered ring fused 2-pyridone. The resulting molecular fluorophores are hypothesized to be located on the surface and/or inside the CNDs. However, as

the pyrolysis proceeds, carbon cores are formed with a concomitant consumption of molecular fluorophores, a decrease in the quantum yield and an increase in photostability.^{23,25,30}

Regardless of the top-down or bottom-up strategy used, CNDs are intrinsically heterogeneous materials. Accordingly, the ulterior functionalization of CNDs with diverse compounds, including CDs, yields composites that are not well defined in terms of structure and composition. In order to avoid the drawbacks associated with the heterogeneity of CNDs and inspired by the fluorescence properties of citrazinic acid-based molecular fluorophores, we report herein the preparation of IPCA-appended CDs (IPCA-CDs). Two highly efficient synthetic chemical strategies starting from suitable pre-modified monosubstituted CDs (β - and γ -derivatives) are described. We also demonstrate that these engineered FCDs behave as CND-based CD “turn off–on” biosensors using *p*-nitrophenol as a quencher. As a proof-of-concept, we validate their capabilities as a non-enzymatic cholesterol biosensor and as a sensor for β -galactosidase activity.

2. Results and discussion

2.1. Chemical synthesis and characterization of IPCA-appended FCDs

Despite the outstanding optical properties of IPCA derivatives as fluorophores, limited efforts have been devoted to develop synthetic methods that enable their efficient preparation. In the majority of the reported cases, IPCA-based fluorophores are only identified by spectroscopic (NMR and mass) and analytical techniques, and/or isolated in low yields from the prepared CNDs.^{20,24,25} In order to access the engineered FCDs that avoid the drawback of the heterogeneity of the CNDs as a fluorescent material, we envisaged two different strategies for the synthesis of IPCA-appended CDs that are based on the reaction of CA with a suitable α,β -ethylenediamine molecular motif (Scheme 1).

The first approach involves the use of diethylenetriamine (DETA)^{29,31,32} for the preliminary formation of the IPCA skeleton by a reaction with CA, followed by the covalent grafting of the molecular fluorophore obtained to conveniently functionalized α - and γ -CDs. Thus, in a first step 1-(2-aminoethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-*a*]pyridine-7-carboxylic acid (AEIPCA, 1)^{29,31,32} was prepared using a stand-alone procedure by the microwave-assisted condensation reaction of an equimolar aqueous mixture of DETA and CA (300 W, 130 °C, 1.5 h). The procedure is novel, it allows the isolation of AEIPCA in a good yield (49%), and spectroscopic characterization correlates well with the already published data.^{29,31,32} AEIPCA was subsequently grafted to mono 6-vinylsulfone-modified CDs (VS- β -CD and VS- γ -CD, 4 and 5) *via* aza-Michael coupling, exploiting the complementary reactivity of the clickable amine and vinyl sulfone functions.^{33,34} The efficiency and versatility shown by the Michael-type additions of aminated and thiolated nucleophiles to VS in diverse click metal-free (bio)conjugation scenarios have been previously demonstrated by us.^{33–35} The syn-



rescence of **AEIPCA** (**1**), either alone or in the presence of free β - or γ -CD, and IPCA-appended FCDs (**6**, **7** and **10**, **11**). The results (Fig. 1) showed that the fluorescence is quenched by *p*NP regardless of the presence of CDs, although the extent is larger when the IPCA skeleton is covalently bonded to the CD (compounds **6**, **7** and **10**, **11**). However, at the recovery step only the fluorescence of IPCA-appended FCDs is restored upon the addition of Chol. These results point to major differences in the interaction of *p*NP with **AEIPCA** (**1**) and IPCA-appended FCDs. Data suggest the existence of an unspecific interaction, presumably between the primary amino group of **AEIPCA** (**1**) and the phenolate form of *p*NP, to yield a product that is less fluorescent and not disrupted by Chol. Conversely, the interaction of *p*NP with IPCA-appended FCDs relies on the formation of an inclusion complex between the CD moiety and *p*NP, the latter being specifically displaced by Chol. Indeed, in the presence of free β - or γ -CD, Chol leads to a slightly larger quenching of **AEIPCA** (**1**) that can be rationalized as the displacement and release of *p*NP from the inclusion complex with the CD, increasing the amount of *p*NP available to interact with **AEIPCA** (**1**).

The above results on the off/on state of IPCA-appended FCDs resemble those previously described for β -CD-based CND-CDs to detect Chol.¹⁹ A more exhaustive analysis of the effect of *p*NP on the quenching of the fluorescence of IPCA-appended FCDs and the recovery with Chol revealed a linear response with the coefficient of determination $R^2 = 0.99$ (Fig. S4 and S5, ESI†). The time needed to reach the equilibrium for quenching and recovery is 2.5 min and 10 min, respectively (Fig. S6, ESI†), the latter being significantly shorter than the 42 min reported for β -CD-based CND-CDs.¹⁹

To investigate the feasibility of quantifying Chol in real samples, FCD **6** was evaluated using human serum as the matrix. The values of the recovery ratio (Table 1) are analogous to those reported for CND-CDs and calf serum as the matrix, indicating that FCD **6** is suitable for the quantification of Chol in real samples.¹⁹ All these data support the use of IPCA-appended FCDs as Chol sensors in a similar manner as already established for CND-CDs.

2.3. IPCA-appended FCDs as sensors for the determination of β -galactosidase activity

The ability of *p*NP to form an inclusion complex with β -CD and quench the fluorescence of β -CD-based CND-CDs has

Table 1 Assessment of the quantification of Chol using a 25-fold dilution of human serum as the complex matrix

Sample number	Added Chol (μ M)	Sum of added and measured Chol (μ M)	Measured Chol (μ M)	Recovery (%)
1	0	13.0	13.0 \pm 1.2	—
2	20	33.0	36.6 \pm 2.1	110.9
3	40	53.0	58.1 \pm 1.8	109.6
4	60	73.0	73.5 \pm 1.7	100.6
5	80	93.0	99.7 \pm 1.3	107.2

been previously exploited to quantify the activity of β -galactosidase,¹⁷ α -glucosidase,⁴² and alkaline phosphatase.^{15,17} The assays rely on the quenching of the fluorescence by *p*NP released upon the action of the enzyme on an analog of the substrate that bears the *p*NP motif. To further explore the biosensing capabilities of the IPCA-appended FCDs, we decided to investigate these systems as sensors for the determination of β -galactosidase activity. For this purpose, we selected FCD **10**. As expected, this compound proved to be a good system to quantify the activity of β -galactosidase from *E. coli* using *p*-nitrophenyl β -D-galactopyranoside (*p*NPG) as a substrate. The results obtained from the kinetics of 8 min show a linear response in the range of 9–280 mU mL⁻¹ and $R^2 = 0.98$ (Fig. S7, ESI†). These values are basically the same as those reported for β -CD-based CND-CDs,^{15,17} indicating that the role of CNDs in the assay is limited to acting as a support for the molecules responsible for the fluorescence.

The facts that the fluorescence of **AEIPCA** (**1**), either alone or in the presence of free β - or γ -CD, is quenched by *p*NP (Fig. 1), and that the activity of α -glucosidase is determined by uncoated CNDs³⁹ suggest that, providing a suitable substrate, **AEIPCA** (**1**) may be a simpler system to detect enzymes, in general, and β -galactosidase,¹⁷ in particular. To determine the role of β -CD in the quenching of the fluorescence by *p*NP, the activity of *E. coli* β -galactosidase was evaluated using **AEIPCA** (**1**), either alone or in the presence of free β - or γ -CD, and FCDs **10** and **11**, where the fluorophore is covalently bonded to β - and γ -CDs, respectively, as controls. Unexpectedly, at the beginning of the experiment (*i.e.* $t = 0$), the fluorescence of FCDs **10** and **11** was 25% and 60% of that for **AEIPCA** (**1**), which is not affected by the presence of free CDs (Fig. 2),




Fig. 1 Quenching (Q) with *p*NP (40 μ M) and recovery (R) with Chol (100 μ M) of the photoluminescence (PL) of compound **1**, alone or in combination with free β - or γ -CD (compounds **b** and **g**, respectively), and IPCA-CDs (**6**, **7**, **10** and **11**). Values and transparency of the colour are normalized to those before quenching.






Fig. 2 Detection of the activity of *E. coli* β -galactosidase with compound **1** (blue), alone or in combination with an equimolar amount of β -CD (dark green) or γ -CD (red), and compounds **10** (light green) and **11** (yellow). Left: Evolution of the fluorescence intensity as a function of time. Right: Determination of the enzymatic activity.

despite they sharing similar QY (Table S1, ESI[†]). This result suggests the formation of an inclusion complex between CD and *p*NPG that is plausible according to theoretical calculations.⁴³ However, quenching is evident only when *p*NPG and AEIPCA (**1**) are in close proximity or at a high local concentration, as it is the case for FCDs **10** and **11** due to the covalent bond between the fluorophore and CD:*p*NPG inclusion complex. From the point of view of sensing the enzymatic activity, AEIPCA (**1**) is as suitable as FCDs **10** and **11** because the values of the enzymatic activity are very close, with the coefficient of variation being 0.15.

3. Conclusions

The feasibility of CD-appended CNDs as sensors has been demonstrated by different authors. These sensors rely on the quenching of the fluorescence of the CNDs by a sacrificial quencher, although the heterogeneity of CNDs hinders their characterization at the molecular level. We have deconstructed the CND-CD systems to demonstrate that (i) the role of CNDs is limited to acting as a support for the molecular fluorophores produced during their synthesis and (ii) the molecular fluorophores suffice for the determination of the enzymatic activity based on the quenching by *p*NPG as a sacrificial quencher. Additionally, we have described two novel routes for the functionalization of CDs with the IPCA molecular fluorophore described as being responsible for the fluorescence of the CNDs. The resulting IPCA-appended FCDs (IPCA-CDs) have been demonstrated to share many of the features of CND-CDs responsible for their use as “off-on” sensors.

4. Experimental

4.1. Chemical synthesis

Anhydrous citric acid (CA), cholesterol (Chol), diethylenetriamine (DETA), divinyl sulfone (DVS), ethanolamine, tri-

ethylamine (TEA), 4-nitrophenol (*p*NPG), and 4-nitrophenyl β -D-galacto-pyranoside (*p*NPG) were obtained from Sigma-Aldrich (St Louis, MO, USA). Commercial reagents were used as received without further purification. Mono-6-*O*-toluenesulfonyl- β -cyclodextrin (**2**) and mono-6-(*O*-2,4,6-triisopropylbenzenesulfonyl)- γ -cyclodextrin (**3**)³⁶ were prepared following the already reported procedures. TLC was performed on Merck silica gel 60 F254 aluminium sheets. Flash column chromatography was performed on silica gel (Merck, 230–400 mesh, ASTM). ¹H and ¹³C NMR spectra were recorded at room temperature using a Varian Direct Drive (400, 500, and 600 MHz) spectrometer. Chemical shifts (δ) are given in ppm; *J* values are given in Hz. MALDI-ToF mass spectra were recorded on an Autoflex Bruker spectrometer using HCCA and NaI as matrices. Optical rotations were recorded using a PerkinElmer 341 polarimeter at room temperature. Fluorescence spectra and UV-Vis spectra were recorded using a Varian Cary Eclipse luminescence spectrometer and a Specord 200 Plus Instrument (Analytik Jena), respectively.

4.1.1. Synthesis of 1-(2-aminoethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-*a*]pyridine-7-carboxylic acid (AEIPCA) (1**).** DETA (154 mg, 1.50 mmol) was added to a solution of CA (313 mg, 1.63 mmol) in purified water (40 mL). The reaction mixture was irradiated at 300 W and 130 °C in a Milestone Star Microwave Labstation for 1.5 h. Evaporation of the solvent gave a crude product that was purified by column chromatography (acetonitrile/water/ammonia 8 : 2 : 0.25 to 6 : 2 : 0.5), yielding pyrone derivative **1** (164 mg, 49%); Mp 204 °C (dec); IR (neat): ν = 1636, 1535, 1509, 1490, 1446, 1411, 1368, 1293, 1255, 1104, 761, 707, 609, 590, 549 cm⁻¹; ¹H NMR (D₂O, 400 MHz): 6.10 (d, *J* = 1.2 Hz, 1H), 5.91 (d, *J* = 1.3 Hz, 1H), 4.14 (t, *J* = 8.9 Hz, 2H), 3.77 (t, *J* = 8.9 Hz, 2H), 3.59 (t, *J* = 6.0 Hz, 4H), 3.32 (t, *J* = 6.0 Hz, 2H). ¹³C NMR (D₂O, 126 MHz): δ = 172.71, 162.63, 153.38, 152.38, 103.14, 85.03, 47.49, 44.11, 43.66, 36.72; HR-MS (ESI⁺): *m/z* = found 224.1026, calcd for C₁₀H₁₄N₃O₃ [M + H]⁺: 224.1035.

4.1.2. General procedure for the synthesis of mono-6-VS-modified CDs (4** and **5**).** VS-functionalized CDs were obtained



following the one-pot two-step procedure reported for the synthesis of compound **4**.³⁵ Briefly, ethanolamine (470 μL , 7.75 mmol) was added to a solution of the corresponding mono-6-*O*-sulfonyl CDs (**2** or **3**, 0.38 mmol) in DMF (10 mL). The reaction mixture was irradiated at 500 W and 80 °C in a Milestone Star Microwave Labstation for 1 h. Acetone was added (100 mL), and the resulting precipitate was filtered *in vacuo* and washed with acetone (20 mL) and Et₂O (20 mL) to yield the corresponding intermediate mono-6-deoxy-6-hydroxyethylamino-CD as a solid that was dried *in vacuo* at 50 °C for one day (90 and 88% yields, respectively). To a solution of this intermediate (0.13 mmol) in H₂O (15 mL) was added DVS (26 μL , 0.25 mmol). The reaction mixture was kept at room temperature for 1 h. The solvent was evaporated *in vacuo* (to ~8 mL). Acetone was added (50 mL), and the precipitate was filtered *in vacuo*, washed with acetone (10 mL) and Et₂O (10 mL), and then dried *in vacuo* at 50 °C for one day:

(a) 6-Deoxy-6-(2-hydroxyethyl) ((vinylsulfonyl)methyl)amino- β -cyclodextrin (**4**) was obtained as a solid (140 mg, 85%).³⁵

(b) 6-Deoxy-6-(2-hydroxyethyl) ((vinylsulfonyl)methyl)amino- γ -cyclodextrin (**5**) was obtained as a solid (130 mg, 70%): Mp: 235 °C (dec); IR (neat): $\nu = 3350, 2927, 1738, 1651, 1366, 1154, 1079, 1026, 941, 849, 757, 706, 582, 529 \text{ cm}^{-1}$; $[\alpha]_{\text{D}} +153.6$ (*c* 0.25, H₂O); ¹H NMR (500 MHz, DMSO-*d*₆-D₂O, selected signals) δ : 6.87 (m, 1H), 6.17 (m, 2H), 5.13–4.75 (several brs, 8H); ¹³C NMR (126 MHz, DMSO-*d*₆-D₂O): δ 137.49, 130.27, 102.28, 101.68, 81.44, 80.92, 73.37, 72.94, 72.81, 72.64, 72.35, 59.47, 51.03, 40.02, 39.85, 39.69, 39.52, 39.35, 39.18, 39.02; HR-MS (MALDI-TOF): *m/z* = found 1458.4738, calcd for C₅₄H₉₂NO₄₂S [M + H]⁺: 1458.4815; found 1480.5160, calcd for C₅₄H₉₂NNaO₄₂S [M + Na]⁺: 1480.4634.

4.1.3. General procedure for the VS-based click synthesis of AEIPCA-appended FCDs (6 and 7). To a solution of the corresponding mono-6-VS-modified CDs (**4** or **5**) (0.1 mmol) and the AEIPCA molecular fluorophore **2** (1.1 mmol) in DMSO–water (1:2, 9 mL) was added triethylamine (50 μL , 0.3 mmol). The reaction mixture was heated at 50 °C for 6 h and then acetone (50 mL) was added. The resulting precipitate was collected by centrifugation and successively washed with acetone (40 mL) and ether (40 mL). The obtained solid was purified by column chromatography to yield the corresponding IPCA-appended FCDs (**6** or **7**):

(a) IPCA- β -FCDs (**6**): Column chromatography (acetonitrile/water/ammonia 5:2:0.1) gave **6** (140 mg, 92%) as a solid: Mp: 192 °C (dec); $[\alpha]_{\text{D}} +44.8$ (*c* 0.25, H₂O); IR (neat): $\nu = 3214, 1649, 1551, 1412, 1077, 1028, 612 \text{ cm}^{-1}$; ¹H NMR (500 MHz, DMSO-*d*₆-D₂O, selected signals): δ 5.97 (s, 1H), 5.76 (s, 1H), 4.85 (d, *J* = 3.2 Hz, 1H), 4.83–4.79 (m, 5H), 4.78 (d, *J* = 3.4 Hz, 1H), 3.96 (t, *J* = 8.7 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆): δ 168.09, 160.79, 152.92, 104.34, 102.15, 102.04, 101.97, 101.90, 101.72, 83.82, 81.67, 81.61, 81.54, 81.39, 80.96, 73.17, 73.03, 72.97, 72.93, 72.46, 72.30, 72.19, 72.06, 70.76, 60.09, 59.91, 59.12, 56.10, 54.67, 52.53, 50.17, 47.94, 47.31, 45.76, 45.64, 42.81, 42.19, 40.02, 39.85, 39.69, 39.52, 39.35, 39.19, 39.02; HR-MS (MALDI-TOF): *m/z* = found 1541.5027, calcd for C₅₈H₉₄N₄NaO₄₀S [M + Na]⁺: 1541.5063; found 1519.4538, calcd

for C₅₈H₉₅N₄O₄₀S [M + H]⁺: 1519.5243; found 1557.4644, calcd for C₅₈H₉₄N₄KO₄₀S [M + K]⁺: 1557.4802.

(b) IPCA- γ -FCDs (**7**): Column chromatography (acetonitrile/water/ammonia 6:2:0.1) gave **7** (59 mg, 35%) as a solid: Mp: 198 °C (dec); $[\alpha]_{\text{D}} +76.4$ (*c* 0.25, H₂O); IR (neat): $\nu = 3231, 1736, 1651, 1555, 1417, 1079, 1024, 996, 759, 705, 613, 527 \text{ cm}^{-1}$; ¹H NMR (400 MHz, D₂O, selected signals): δ 6.19 (s, 1H), 6.03 (s, 1H), 5.20–5.09 (m, 8H); ¹³C NMR (126 MHz, DMSO-*d*₆-D₂O): δ 173.47, 164.09, 154.64, 105.26, 103.29, 103.13, 102.02, 84.30, 82.30, 82.28, 82.22, 82.10, 82.05, 82.02, 80.60, 74.52, 74.49, 74.42, 74.34, 74.28, 73.97, 73.80, 73.70, 73.67, 73.52, 73.48, 73.45, 73.37, 73.29, 73.22, 73.15, 61.67, 61.60, 61.48, 59.26, 57.81, 56.50, 51.68, 51.17, 49.18, 47.99, 46.43, 45.15, 44.88, 42.01, 40.03, 39.86, 39.69, 39.52, 39.35, 39.18, 39.01; HR-MS (MALDI-TOF): *m/z* = found 1681.5402, calcd for C₆₄H₁₀₅N₄O₄₅S [M + H]⁺: 1681.5772; found 1703.5564, calcd for C₆₄H₁₀₄N₄NaO₄₅S [M + Na]⁺: 1703.5591; found 1719.5828, calcd for C₆₄H₁₀₄KN₄O₄₅S [M + K]⁺: 1719.5330.

4.1.4. General procedure for the synthesis of mono-DETA-modified CDs (8 and 9). DETA-functionalized CDs were obtained following a procedure already reported for the synthesis of compound **8**³⁷ with minor modifications. In brief, the corresponding mono-6-*O*-sulfonyl CDs (**2** or **3**, 0.4 mmol) were suspended in DETA (2.5 mL, 23 mmol) under a N₂ atmosphere and the resulting reaction mixture was heated in a sealed reactor (70 °C, 12 h) using an oil bath. After cooling to room temperature, the crude reaction product was poured into acetone (150 mL). The resulting precipitate was collected by centrifugation and successively washed with acetone (2 \times 25 mL). The obtained DETA-modified CDs (**8** and **9**) were used without further purification.

DETA- γ -CD (**9**): Mp: 216 °C (dec); $[\alpha]_{\text{D}} +125.6$ (*c* 0.25, H₂O); IR (neat): $\nu = 3320, 2925, 1738, 1651, 1366, 1154, 1079, 1025, 940, 847, 757, 705, 581, 527 \text{ cm}^{-1}$; ¹H NMR (400 MHz, D₂O): δ 5.43 (s, 1H), 5.27–5.05 (m, 7H), 4.07–3.77 (several multiples, 32H), 3.74–3.57 (several m, 16H), 3.47 (m, 2H), 3.01 (m, 2H), 2.92–2.80 (several m, 4H); ¹³C NMR (101 MHz, D₂O) δ 101.73, 101.63, 80.43, 80.17, 73.30, 72.91, 72.27, 71.79, 71.55, 71.18, 69.33, 60.49, 60.25, 47.53, 47.32, 47.24, 38.69; HR-MS (ES⁺-TOF): *m/z* = found 1382.5306, calcd for C₅₂H₉₂N₃O₃₉ [M + H]⁺: 1382.5308.

4.1.5. General procedure for the *in situ* CA-based synthesis of IPCA-appended FCDs (10 and 11). A solution of the corresponding DETA-modified CDs (**8** or **9**) (0.50 mmol) and CA (0.40 mmol) in water (10 mL) was heated at 160 °C in a sealed Teflon reactor under pressure for 2 h. After cooling to room temperature, the solvent was evaporated *in vacuo* and the resulting solid was purified by column chromatography to yield IPCA-appended FCDs (**10** and **11**):

(a) IPCA- β -FCDs (**10**): Column chromatography (acetonitrile/water/ammonia 5:2:0.1) gave **10** (280 mg, 42%) as a solid: Mp: 228 °C (dec); $[\alpha]_{\text{D}} +91.6$ (*c* 0.25, H₂O); IR (neat): $\nu = 3214, 1717, 1651, 1553, 1366, 1230, 1151, 1076, 1022, 946, 753, 704, 610, 576, 528 \text{ cm}^{-1}$; ¹H NMR (500 MHz, D₂O, selected signals): δ 6.15 (s, 1H), 6.00 (s, 1H), 5.15–4.99 (m, 7H), 4.19 (t, *J* = 8.7 Hz, 2H); ¹³C NMR (126 MHz, D₂O): δ 175.82, 165.53, 156.26,



155.72, 105.60, 104.55, 104.18, 87.90, 86.14, 84.19, 83.84, 83.73, 83.43, 75.80, 75.67, 75.20, 74.77, 74.56, 74.53, 74.43, 74.39, 63.42, 63.01, 62.88, 62.79, 51.70, 50.21, 48.06, 46.85, 46.47; HR-MS (ES⁺-TOF): m/z = found 1340.4678, calcd for C₅₂H₈₁N₃O₃₇ [M + H]⁺: 1340.4627.

(b) **IPCA- γ -FCDs (11)**: Column chromatography (acetonitrile/water/ammonia 6:2:0.1) gave **11** (195 mg, 26%) as a solid: Mp: 213 °C (dec); [α]_D +70.8 (*c* 0.25, H₂O); IR (neat): ν = 3214, 1646, 1552, 1420, 1078, 1026, 941, 757, 613, 528 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆-D₂O, selected signals): δ 5.98 (s, 1H), 5.80 (s, 1H), 4.86 (m, 8H); ¹³C NMR (126 MHz, D₂O): δ 172.95, 162.80, 153.30, 152.93, 103.51, 101.73, 101.67, 101.61, 101.57, 101.49, 100.74, 85.16, 82.72, 80.79, 80.50, 80.40, 80.35, 80.29, 79.11, 74.67, 73.29, 72.90, 72.84, 72.71, 72.36, 72.28, 72.24, 72.13, 72.04, 72.01, 71.85, 71.78, 71.71, 71.63, 71.55, 67.32, 66.00, 60.71, 60.27, 60.21, 60.14, 59.92, 48.61, 47.64, 45.13, 44.80, 43.76, 43.20; HR-MS (ESI⁻): m/z = found 1500.5084, calcd for C₅₈H₉₀N₃O₄₂ [M - H]⁻: 1500.5004, found 749.7476, calcd for C₅₈H₈₉N₃O₄₂ [M - 2H]²⁻: 749.7466.

4.2. Fluorescence studies

4.2.1 Quantum yield. Fluorescence quantum yield (QY) was estimated using quinine sulfate dissolved in 0.1 M H₂SO₄ as a standard (QY_{st} = 0.54) and applying the following equation:

$$QY = QY_{st} (m_{sm}/m_{st})(\eta^2_{sm}/\eta^2_{st})$$

where QY_{st} is the QY of the standard, m is the slope of the plot fluorescence intensity vs. absorbance at the excitation maxima for the sample (sm) and the standard (st), and η is the refractive index. Samples were dissolved in Milli-Ro water (conductivity: 18.2 M ω cm) to values of absorbance <0.1 and the integrated emission intensities were recorded.

4.2.2. Determination of the lag time. The fluorescence of a solution of 2.5 mL of IPCA-CD (2 μ g mL⁻¹) in phosphate buffered solution was monitored as a function of time upon the addition of *p*NP (50 μ L, 10 mM). Once no change in the fluorescence was detected, Chol in EtOH (125 μ L, 2 mM) was added and the recovery of the fluorescence was monitored for 15 min. The excitation and emission wavelengths were 365 nm and 435 nm, respectively.

4.2.3. Quenching of the fluorescence by *p*-nitrophenol. The fluorescence of a phosphate buffered solution of IPCA-CDs (2.5 mL, 2 μ g mL⁻¹) was monitored as a function of the concentration of *p*NP. Successive amounts of *p*NP (10 mM) were added to reach a final concentration of up to 40 μ M. After incubation (5 min), the sample was excited at 365 nm and the intensity emitted in the range of 375–625 nm was recorded.

4.2.4. Recovery of the fluorescence by Chol. The fluorescence of a phosphate buffered solution of IPCA-CDs (2.5 mL, 2 μ g mL⁻¹) quenched with *p*NP (40 μ M) was monitored as a function of the concentration of Chol. Successive amounts of Chol in EtOH (2 mM) were added to reach a final concentration of up to 180 μ M. After incubation (15 min), the

sample was excited at 365 nm and the emitted intensity in the range of 375–625 nm was recorded.

4.3. Fluorimetric assays

4.3.1. Detection of Chol in human serum as a matrix. A phosphate buffered solution of **6** (2400 μ L, 2 μ g mL⁻¹) supplemented with *p*NP (10 μ L, 2 mM) was combined with human serum (100 μ L) from healthy volunteers. The samples were spiked with different amounts of Chol (20, 40, 60, and 80 μ M). After incubation (10 min), the emission at 435 nm (excitation at 365 nm) was monitored.

4.3.2. β -Galactosidase activity. β -Galactosidase activity was assayed in 25 mM HEPES, pH 7.3, 20 μ M MgCl₂, 200 μ M *p*NPG and *E. coli* β -galactosidase (14 U L⁻¹). The sensing system consisted of either 210 μ M IPCA-CD or compound **1** plus IPCA-CD (equimolecular amount). The solution was excited at 365 nm and the fluorescence emitted at 435 nm was recorded every 30 seconds for 15 min. The activity was estimated as the slope of the plot I/I_0 vs. time for the first 8 min. At the optimal time of assay (8 min), the enzymatic activity of *E. coli* β -galactosidase was assayed in a range of 9.3–280 U L⁻¹.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by grant no. CTQ2017-86125-P and CTQ2016-78754-C2-1-R (Ministerio de Economía, Industria y Competitividad, Spain).

References

- 1 R. N. Dsouza, U. Pischel and W. M. Nau, *Chem. Rev.*, 2011, **111**, 7941–7980.
- 2 R. Pinalli, A. Pedrini and E. Dalcanale, *Chem. Soc. Rev.*, 2018, **47**, 7006–7026.
- 3 A. Ueno, *Supramol. Sci.*, 1996, **3**, 31–36.
- 4 H. Ikeda, in *Artificial Receptors for Chemical Sensors*, ed. V. M. Y. Mirsky and A. K. Yatsimirsky, Wiley, 2011, ch. 4, pp. 113–114.
- 5 T. Ogoshi and A. Harada, *Sensors*, 2008, **8**, 4961–4982.
- 6 G. Benkovics, M. Malanga and E. Fenyvesi, *Int. J. Pharm.*, 2017, **531**, 689–700.
- 7 G. Cutrone, J. M. Casas-Solvas and A. Vargas-Berenguel, *Int. J. Pharm.*, 2017, **531**, 621–639.
- 8 H. Shelley and R. J. Babu, *J. Pharm. Sci.*, 2018, **107**, 1741–1753.
- 9 H. T. Shi, J. F. Wei, L. Qiang, X. Chen and X. W. Meng, *J. Biomed. Nanotechnol.*, 2014, **10**, 2677–2699.
- 10 S. Y. Lim, W. Shen and Z. Gao, *Chem. Soc. Rev.*, 2015, **44**, 362–381.



- 11 X. Sun and Y. Lei, *TrAC, Trends Anal. Chem.*, 2017, **89**, 163–180.
- 12 H. Behboudi, G. Mehdipour, N. Safari, M. Pourmadadi, A. Saei, M. Omid, L. Tayebi and M. Rahmandoust, in *Advanced Structured Materials*, 2019, vol. 104, pp. 145–179.
- 13 A. Cayuela, M. Laura Soriano and M. Valcárcel, *Analyst*, 2016, **141**, 2682–2687.
- 14 Z.-Y. Lin, Y.-C. Kuo, C.-J. Chang, Y.-S. Lin, T.-C. Chiu and C.-C. Hu, *RSC Adv.*, 2018, **8**, 19381–19388.
- 15 C. Tang, Z. Qian, Y. Huang, J. Xu, H. Ao, M. Zhao, J. Zhou, J. Chen and H. Feng, *Biosens. Bioelectron.*, 2016, **83**, 274–280.
- 16 C. Tang, J. Zhou, Z. S. Qian, Y. Y. Ma, Y. Y. Huang and H. Feng, *J. Mater. Chem. B*, 2017, **5**, 1971–1979.
- 17 M. Mao, T. Tian, Y. He, Y. Ge, J. Zhou and G. Song, *Microchim. Acta*, 2018, **185**, 1–6.
- 18 M. Luo, Y. F. Hua, Y. R. Liang, J. J. Han, D. H. Liu, W. T. Zhao and P. Wang, *Biosens. Bioelectron.*, 2017, **98**, 195–201.
- 19 Q. Sun, S. Fang, Y. Fang, Z. Qian and H. Feng, *Talanta*, 2017, **167**, 513–519.
- 20 D. Qu and Z. Sun, *Mater. Chem. Front.*, 2020, **4**, 400–420.
- 21 M. K. Barman and A. Patra, *J. Photochem. Photobiol. C*, 2018, **37**, 1–22.
- 22 Y. Xiong, J. Schneider, E. V. Ushakova and A. L. Rogach, *Nano Today*, 2018, **23**, 124–139.
- 23 S. J. Zhu, X. H. Zhao, Y. B. Song, S. Y. Lu and B. Yang, *Nano Today*, 2016, **11**, 128–132.
- 24 W. Kasprzyk, S. Bednarz and D. Bogdal, *Chem. Commun.*, 2013, **49**, 6445–6447.
- 25 Y. B. Song, S. J. Zhu, S. T. Zhang, Y. Fu, L. Wang, X. H. Zhao and B. Yang, *J. Mater. Chem. C*, 2015, **3**, 5976–5984.
- 26 W. Kasprzyk, S. Bednarz, P. Zmudzki, M. Galica and D. Bogdal, *RSC Adv.*, 2015, **5**, 34795–34799.
- 27 J. Zhang, L. Yang, Y. Yuan, J. Jiang and S.-H. Yu, *Chem. Mater.*, 2016, **28**, 4367–4374.
- 28 J. Schneider, C. J. Reckmeier, Y. Xiong, M. von Seckendorff, A. S. Susha, P. Kasak and A. L. Rogach, *J. Phys. Chem. C*, 2017, **121**, 2014–2022.
- 29 X. Meng, Y. Wang, X. Liu, M. Wang, Y. Zhan, Y. Liu, W. Zhu, W. Zhang, L. Shi and X. Fang, *Opt. Mater.*, 2018, **77**, 48–54.
- 30 M. Shamsipur, A. Barati, A. A. Taherpour and M. Jamshidi, *J. Phys. Chem. Lett.*, 2018, **9**, 4189–4198.
- 31 X. Liu, H.-B. Li, L. Shi, X. Meng, Y. Wang, X. Chen, H. Xu, W. Zhang, X. Fang and T. Ding, *J. Mater. Chem. C*, 2017, **5**, 10302–10312.
- 32 W. K. Zhang, L. J. Shi, Y. Q. Liu, X. R. Meng, H. Xu, Y. Q. Xu, B. Y. Liu, X. M. Fang, H. B. Li and T. Ding, *RSC Adv.*, 2017, **7**, 20345–20353.
- 33 J. Morales-Sanfrutos, J. Lopez-Jaramillo, M. Ortega-Munoz, A. Megia-Fernandez, F. Perez-Balderas, F. Hernandez-Mateo and F. Santoyo-Gonzalez, *Org. Biomol. Chem.*, 2010, **8**, 667–675.
- 34 F. J. Lopez-Jaramillo, F. Hernandez-Mateo and F. Santoyo-Gonzalez, in *Integrative Proteomics*, ed. H. C. M. Leung, T.-K. Man and R. J. Flores, IntechOpen, 2012, pp. 301–326.
- 35 T. del Castillo, J. Morales-Sanfrutos, F. Santoyo-Gonzalez, S. Magez, F. J. Lopez-Jaramillo and J. A. Garcia-Salcedo, *ChemMedChem*, 2014, **9**, 383–389.
- 36 R. Palin, S. J. A. Grove, A. B. Prosser and M. Q. Zhang, *Tetrahedron Lett.*, 2001, **42**, 8897–8899.
- 37 R. J. Jiang, B. Yang, D. Yi, F. Wang, B. Han, Y. L. Zhao, X. L. Liao, J. Yang and C. Z. Gao, *J. Polym. Eng.*, 2014, **34**, 133–139.
- 38 W. Kasprzyk, P. Krzywda, S. Bednarz and D. Bogdal, *RSC Adv.*, 2015, **5**, 90473–90477.
- 39 S. Huang, E. L. Yang, J. D. Yao, Y. Liu and Q. Xiao, *Microchim. Acta*, 2018, **185**, 9333–9342.
- 40 N. Xiao, S. G. Liu, S. Mo, N. Li, Y. J. Ju, Y. Ling, N. B. Li and H. Q. Luo, *Talanta*, 2018, **184**, 184–192.
- 41 M. Zheng, Z. Xie, D. Qu, D. Li, P. Du, X. Jing and Z. Sun, *ACS Appl. Mater. Interfaces*, 2013, **5**, 13242–13247.
- 42 S. Y. Liu, H. Wang, T. He, L. Qi and Z. Q. Zhang, *Luminescence*, 2016, **31**, 96–101.
- 43 S. S. Kiselev and Y. A. Borisov, *J. Struct. Chem.*, 2016, **57**, 849–854.

